Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | OGG1 | O15527 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31421812 | 1.00 | RXRA (0.44) | RXRARXRBRXRGPPARGP2RX1 | |
| SCHEMBL23519071 | 0.82 | NOTUM (0.47) | P2RX1FFAR1 | |
| SCHEMBL23519098 | 0.81 | PPARG (0.45) | PPARGFFAR1NR4A2 | |
| SCHEMBL23519064 | 0.79 | PPARG (0.51) | PPARGKDM4ENR4A2 | |
| SCHEMBL3374117 | 0.79 | PPARA (0.64) | PPARGPPARDKDM4EOGG1PKM | |
| SCHEMBL31433030 | 0.79 | KMT2A (0.46) | KDM4ELMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23519058 | 0.79 | KAT6A (0.38) | PPARGFFAR1NR4A2 | |
| SCHEMBL26125657 | 0.79 | LMNA (0.51) | PPARGLMNACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL17674534 | 0.79 | SSTR4 (0.43) | PPARGCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL23519083 | 0.78 | PPARA (0.61) | PPARGPPARDCYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-12 | — | — | US | disclosed |
| EP-4499224-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023187677-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-05 | — | — | WO | disclosed |
| US-20210179554-A1 | ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | SSTR4, SSTR3, SSTR1 | RXRA 1124/4885RXRB 1866/4885RXRG 1436/4885 |
| US-20210179554-A1 | ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SLC6A5, LIFR, SLC6A9 | RXRA 3630/4885RXRB 3734/4885RXRG 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.